Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
'After living in a country with hazy skies and a billion people, it is breathtaking when the sky is blue, the air crisply clean and there is drinking water in the taps. And, joy of joys, hardly any people.'
Almost 2,000 companies whose private provident and pension funds have invested in non-convertible debentures of IL&FS group firms are staring at the prospect of booking losses to the tune of Rs 9,000 crore or more if the interest income is added.
The index rising for the fourth straight session surged 564 points.
The 50-issue NSE Nifty in range-bound movements settled higher by 59.15 points, or 0.58 per cent, at 10,252.10.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
The benchmark Sensex gained 4,642.84 points, or 16.%, while the broader NSE Nifty surged 1,572.85 points, or 18.20% during this period.
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
Stocks reeled under huge losses on Thursday as the benchmark Sensex plunged sharply by over 465 points, the biggest single-day fall in three months, after India carried out "surgical strikes" on Wednesday night on terror launch pads across the Line of Control.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Brokerages expect Nifty50 firms to post 11.8% growth in net profit in Q1 but sales may decline
Data also show that several other leading domestic pharma companies have recalled their products from the US
How did marquee Dalal Street investors fare in the Jan-Mar quarter that saw the BSE Sensex tank 10 per cent?
Top corporates have paid more advance tax in second quarter this year.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
The S&P BSE Sensex dropped 207 points to end at 25,230.
Is yet to decide about the partnership or acquisition route
The analysis covers BSE 200 Index's 171 companies for which data on the compensation to the boards of directors for FY14 and FY13 are available.
Traders are closely watching the progress of the monsoon.
Next set of Q4 FY16 earnings, progress of monsoon along with election poll outcome will dictate market trend this week
Consumer businesses come to the rescue of large conglomerates in the midst of a meltdown in commodities.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Midcap stocks continued to remain on buyers' radar with BSE Midcap index up 0.1%.
Tata Consultancy Services (TCS), HCL Technologies and HDFC Bank are among the 50 best public companies in Asia-Pacific according to a compilation by Forbes, which ranked India second behind China as home to the "world's next growth engines".
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
TCS tops the list of 100 wealth creators for the fourth time in a row
The rupee resumed lower at 63.65 per dollar as against previous closing of 63.58 at the Interbank Foreign Exchange (Forex) market.
It's time for Indian generic companies to rethink their strategies.
Experts say the stock market correction in recent times increases the risk-reward in favour of large-cap stocks.
The BSE Mid-cap index gained 1.1% while the Small-cap index surged 1.3%, outperforming the benchmark indices
While gold returned 12 per cent annual gain in 10 years, Nifty didn't exceed 9 per cent.
Impact of the slowdown is most visible among promoter/owner-CEOs
Investors continue to make losses on investments.
'We have seen a host of businesses across sectors generate economic value and wealth for investors.'
Besides foreign flows, corporate earnings and US Federal Reserve chief Janet Yellen's testimony to the nation's legislature are also likely to impact investor sentiment.
Raising concern about over-dependence of Indian capital markets on foreign institutional investors, eminent banker Deepak Parekh has said that something needs to be done to change this pattern.
Cipla, though late in changing its strategy for international markets, has in recent years taken an inorganic route for expansion.
Not much is heard or read about Sun Pharma's media-shy owner.
